|
15 Jul 2021 |
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
|
|
15 Jul 2021 |
Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)
|
|
15 Jul 2021 |
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
|
|
15 Jul 2021 |
Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)
|
|
15 Jul 2021 |
Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials
|
|
15 Jul 2021 |
Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab
|
|
15 Jul 2021 |
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
|
|
15 Jul 2021 |
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
|
|
15 Jul 2021 |
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
|
|
15 Jul 2021 |
Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome
|
|
15 Jul 2021 |
Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005
|
|
15 Jul 2021 |
Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus
|
|
15 Jul 2021 |
Lilly Announces Acquisition of Protomer Technologies
|
|
13 Jul 2021 |
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
|
|
13 Jul 2021 |
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy
|
|
13 Jul 2021 |
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
|
|
13 Jul 2021 |
ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells
|
|
13 Jul 2021 |
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma
|
|
13 Jul 2021 |
Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158
|
|
13 Jul 2021 |
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors
|
